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from dogs undergoing surgery with concurrent
gross splenic and hepatic masses: 125 cases
(2012–2016)
Fernando J. Leyva1*, Catherine A. Loughin1, Curtis W. Dewey1,2, Dominic J. Marino1, Meredith Akerman3
and Martin L. Lesser3

Abstract
Objective: To investigate the histopathologic characteristics of concurrent splenic and liver masses in dogs undergoing splenectomy and liver mass biopsy/resection. Medical records of 125 client-owned dogs found to have splenic
mass or masses and a liver mass or masses during surgery were examined. Signalment (age, sex, breed), body weight,
and results of histopathology were recorded for all dogs.
Results: Twenty-seven percent (34/125) of the dogs in this study had no evidence of malignancy in either the liver or
the spleen. Sixty of 125 dogs (48.0%) had malignancy in the spleen and liver, and 56 (56/60, 93.3%) of those dogs had
the same malignancy in both organs. Signalment was similar to that in other reports of splenic pathology. In this clinical population of dogs, 27% of dogs with concurrent gross splenic and liver masses discovered intraoperatively had
benign lesions in both locations and therefore had a favorable prognosis.
Keywords: Canine biopsies, Dog biopsies, Splenic mass, Hepatic mass, Histopathology, Hemangiosarcoma
Introduction
Splenic masses are frequently encountered in dogs. They
may be diagnosed in dogs that present with non-traumatic hemoabdomen or incidentally upon imaging or
surgery. Lesions in the spleen may be the result of benign
(i.e. lymphoid hyperplasia, hematoma, cyst, abscess, etc.)
or malignant (i.e. hemangiosarcoma (HSA), metastatic
sarcoma/carcinoma, malignant histiocytosis, lymphosarcoma (LSA), etc.) processes [1–4]. Hemangiosarcoma has
been reported by some researchers as the most common
splenic mass in dogs [1, 5]; however, others have reported
higher prevalence of benign lesions [2–4]. In contrast, the
prevalence of benign versus malignant lesions has been
well established in dogs with non-traumatic hemoabdomens. The study by Johnson et al. [5] proposed the “law of
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two-thirds” in dogs with non-traumatic hemoabdomens,
in which two-thirds of dogs with splenomegaly have neoplasia and two-thirds of these had hemangiosarcoma.
Similar to splenic masses, hepatic masses may be
benign (i.e. nodular hyperplasia (NH), extramedullary
hematopoiesis, cyst, abscess, hematoma, etc.) or malignant (i.e. hepatocellular carcinoma (HCC), LSA, malignant histiocytosis, HSA, metastatic carcinoma/sarcoma,
etc.) [6–9]. The presence of a concurrent hepatic mass
or masses (HM) with a splenic mass or masses (SM) has
been reported to be associated with a metastatic disease
process [10, 11]. Hemangiosarcoma and other malignant
splenic neoplasms have been reported to metastasize to
the liver, via splenic venous blood, lymphatic drainage,
or transcoelomic metastasis [12, 13]. However, it has also
been reported that there is a high prevalence of benign
hyperplastic hepatic nodules in dogs with increasing age
[14]. The presence of HM, SM, and the potential for gross
metastatic disease are important considerations for many
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clients in determining whether they wish to accept the
costs, risks, and morbidity associated with surgery given
the possibility of a poor long-term prognosis [15].
The purpose of this retrospective study was to describe
the prevalence of benign versus malignant masses in
dogs with SM and HM undergoing surgery, and to report
patient signalment (age, sex, breed), weight, and histopathological diagnosis of both organs.

Main text
Methods
Inclusion criteria/case selection

A database search in infinity1 of our medical records
revealed 369 splenectomies which were performed
between January 1, 2012, and January 1, 2016. The medical records of all 369 dogs were reviewed. Only dogs with
both SM and HM found at surgery were included in this
study. One hundred twenty-five client-owned dogs were
identified with confirmed SM and HM at the time of surgery and were included in this study. Data obtained from
the medical records included histopathological diagnosis
of both splenic and hepatic tissue, signalment (age, sex,
breed), and body weight. All surgeries were performed by
surgeons (ACVS diplomates) or surgical residents under
supervision of ACVS diplomates, after written consent
was provided by the owners. Each dog had a splenectomy
performed in conjunction with a liver biopsy (via liver
lobectomy or incisional biopsy).
Histopathologic evaluation

Following splenectomy, each whole spleen and liver
sample were fixed in 10% buffered formalin, and were
reviewed by board-certified pathologists from a local,
outside laboratory (Antech Diagnostics2). Sections from
microscopic examination were selected from various
regions of the spleen and liver samples submitted; generally multiple sections were obtained from the margin of any nodule and adjacent unaffected parenchyma.
Microscopic evaluation of multiple selected sections
was accomplished from 4- to 6-μm sections of paraffinembedded tissue mounted on glass microslides and
stained with hematoxylin and eosin. Additional stains
were performed at the discretion of the pathologist.
Based on the microscopic features of the tissues, the
lesions were characterized histologically.
Statistical analysis

Descriptive statistics (mean, SD, median, minimum,
and maximum values for age and weight; frequency and
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percentage for categorical variables such as sex, breed,
benign or malignant lesions, type of lesion) were calculated for the study sample. A cross-tabulation of spleen
and liver status (benign or malignant) was constructed to
determine the percent of dogs with benign splenic lesions
and benign liver lesions, the percent of dogs with benign
splenic lesions and malignant liver lesions, the percent of
dogs with malignant splenic lesions and malignant liver
lesions, and the percent of dogs with malignant splenic
lesions and benign liver lesions.
Inferential statistics were also conducted for the study
sample. After testing for equality of variance by Levene’s
test, a series of independent-samples t tests were conducted for age and weight. A series of Chi squared analyses for patient sex was also conducted. Values of P ≤ 0.05
were considered significant for all analyses. All analyses
were performed using SAS version 9.4.3
Results

There were 125 dogs included in this study. Mean age
was 10.1 years (range 4–15 years). There were one female
intact, 59 female spayed, 11 male intact, and 54 male
neutered. Mean weight was 27.8 kg (range 4–58.3 kg).
There were 42 mixed breed dogs; 24 Golden R etrievers; 7 Labrador Retrievers; 6 German Shepherd Dogs; 4
Beagles; 3 each Cocker Spaniels, Rottweilers, and Yorkshire Terriers; 2 each Australian Shepherd, Cane Corso,
English Springer Spaniel, and Pekingese; and 1 each of 25
other breeds. There were no significant differences in age,
weight, or sex between dogs with malignant lesions versus those with concurrent benign lesions. The data generated and analyzed, examining these associations, are
summarized in Additional file 1.
Of the 125 dogs, 42 (33.6%) had benign SM and 83
(66.4%) had malignant SM. One of the dogs had two
malignant SM. The most common malignant splenic
lesion was HSA (69/84, 82.1%). The most common
benign splenic lesion was NH (27/62, 43.5%). Sixtyseven dogs (53.6%) had malignant HM. The most common malignant hepatic lesion was HSA (51/68, 75%).
The most common benign hepatic lesion was NH (26/69,
37.7%). All biopsy results and number of dogs per type
(benign versus malignant) are summarized in Tables 1
and 2.
Thirty-four of the dogs (27%) had benign SM and
HM. Of the 60 dogs with malignant splenic and liver
lesions, 56 (93.3%) had the same malignancy in both
organs. Forty-six dogs (76.7%) had HSA in the spleen
and the liver, 3 (5%) dogs had leiomyosarcoma (LMS)
in both organs, 3 (5%) dogs had histiocytic sarcoma in
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Table 1 Summarization
of
for spleen and liver biopsies

histopathology

Splenic biopsies obtained
in the study

No. (%
of total)

results

No. (% of 125
dogs)

Malignant splenic lesions
Hemangiosarcoma

Table 1 (continued)
Liver biopsies obtained in the study No. (%
of total)

No. (% of 125
dogs)

Necrosis

2 (2.9)

2 (1.6)

Cirrhosis

2 (2.9)

2 (1.6)

Extramedullary hematopoiesis

1 (1.4)

1 (0.8)

69 (82.1)

69 (55.2)

Leiomyosarcoma

4 (4.8)

4 (3.2)

Hematoma

1 (1.4)

1 (0.8)

Histiocytic sarcoma

3 (3.6)

3 (2.4)

Lipogranuloma

1 (1.4)

1 (0.8)

Undifferentiated sarcoma

2 (2.4)

2 (1.6)

Lymphohistiocytic hepatitis

1 (1.4)

1 (0.8)

Anaplastic spindle cell sarcoma

1 (1.2)

1 (0.8)

Congestion

1 (1.4)

1 (0.8)

Stromal sarcoma

1 (1.2)

1 (0.8)

Infarct

1 (1.4)

1 (0.8)

Osteosarcoma

1 (1.2)

1 (0.8)

Cholestasis

1 (1.4)

1 (0.8)

Mast cell tumor

1 (1.2)

1 (0.8)

Total No. benign liver lesions (%)

69 (100)a

69 (55.2)a

a

Liposarcoma

1 (1.2)

1 (0.8)

Lymphosarcoma

1 (1.2)

1 (0.8)

84 (100)a

84 (67.2)a

Nodular hyperplasia

27 (43.5)

27 (21.6)

Hematoma

11 (17.7)

11 (8.8)

Total No. malignant splenic lesions (%)

Some dogs had multiple lesions on histopathology, thus absolute numbers
and percentages do not add up to 125 and 100% respectively

Benign splenic lesions

Infarct
Extramedullary hematopoiesis

5 (8.1)

5 (4)

4 (6.5)

4 (3.2)

Myelolipoma

3 (4.8)

3 (2.4)

Plaques

3 (4.8)

3 (2.4)

Necrosis

2 (3.2)

2 (1.6)

Splenitis

2 (3.2)

2 (1.6)

Congestion

2 (3.2)

2 (1.6)

Lipoma

1 (1.6)

1 (0.8)

Lymphoid hyperplasia

1 (1.6)

1 (0.8)

Hemosiderosis

1 (1.6)

1 (0.8)

62 (100)a

62 (49.6)a

Total No. benign splenic lesions (%)

Liver biopsies obtained in the study No. (%
of total)

No. (% of 125
dogs)

Malignant liver lesions
Hemangiosarcoma

51 (75)

51 (40.8)

Table 2 Number of dogs per type of splenic mass(es) (SM)
and hepatic mass(es) (HM)

Malignant SM

Malignant HM

Benign HM

Sum
total
of dogs

60

23

83a

Benign SM

8

34

42

Sum total of dogs

68

57

125

a

One dog had two malignant splenic lesions

both organs (one of these dogs additionally had splenic
HSA), 1 (1.7%) dog had liposarcoma in both organs,
one dog had anaplastic sarcoma in both organs, one
dog had undifferentiated sarcoma in both organs, and
1 dog had LSA in both organs. In the four dogs with
exclusively different malignancies, one dog had liposarcoma in the spleen and LSA in the liver, one dog had
osteosarcoma in the spleen and undifferentiated sarcoma in the liver, one dog had LMS in the spleen and
stromal sarcoma in the liver, and the last dog had mast
cell tumor in the spleen and HSA in the liver. Seven of
the dogs (5.6%) with benign SM had malignant HM, 23
of the dogs (18.4%) with malignant SM had benign HM.
The more salient numbers and percentages of dogs with
benign and malignant lesions are summarized in Fig. 1.

Hepatocellular carcinoma

4 (5.9)

4 (3.2)

Histiocytic sarcoma

3 (4.4)

3 (2.4)

Leiomyosarcoma

3 (4.4)

3 (2.4)

Lymphosarcoma

2 (2.9)

2 (1.6)

Undifferentiated sarcoma

2 (2.9)

2 (1.6)

Anaplastic spindle cell sarcoma

1 (1.5)

1 (0.8)

Liposarcoma

1 (1.5)

1 (0.8)

Stromal sarcoma

1 (1.5)

1 (0.8)

68 (100)a

68 (54.4)a

Nodular hyperplasia

26 (37.7)

26 (20.8)

Discussion

Hydrophic vacuolar hepatopathy

16 (23.2)

16 (12.8)

Hepatoma

6 (8.7)

6 (4.8)

Hepatitis

4 (5.8)

4 (3.2)

Cholangiohepatitis

2 (2.9)

2 (1.6)

Fibrosis

2 (2.9)

2 (1.6)

Lymphoplasmacytic hepatitis

2 (2.9)

2 (1.6)

The identification of concurrent SM and HM poses a
conundrum to clinicians. While the incidence of splenic
malignancy in SM and non-traumatic hemoabdomens has
been well-documented [1, 2, 16, 17], only two studies have
looked at the association of HM in dogs with splenic HSA
[11, 18]. Our study is the first to report the prevalence of
benign versus malignant masses in dogs with concurrent

Total No. malignant liver lesions (%)
Benign liver lesions
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56, 45%

31, 25%

Benign Spleen and Liver
Malignant Spleen or Liver

60, 48%
34, 27%
4, 3%

Malignant Spleen and Liver with
Same Pathology
Malignant Spleen and Liver with
Different Pathology

Fig. 1 Numbers and percentages of benign and malignant SM and HM (n = 125)

SM and HM undergoing splenectomy. Our study documents that 27% of dogs with SM and HM have benign
pathology at both sites and therefore carry a good prognosis. The present study also documents that 48% of dogs
with SM and HM have malignant pathology at both sites.
Of the 69 dogs in our study that were diagnosed with
splenic HSA, 46 (66.7%) had HSA diagnosed in the liver;
this is comparable to the results reported by Clendaniel
et al. [11] where 29 of 58 (50%) of dogs with gross liver and
splenic lesions had splenic HSA metastasis to the liver.
There are a multitude of studies documenting the signalment (age, sex, breed) of dogs with SM [3–5, 15, 18–
20]. Multiple studies have found no significant difference
in the age of dogs diagnosed with benign versus malignant SM [3, 5, 18, 19]. The present study demonstrates no
significant difference in the age of dogs presenting with
both SM and HM (10.1 years), versus those of the previously reported studies of SM alone.
Previous studies have found no consistent sex predilection for dogs with benign or malignant SM [5, 20]. The
current study similarly did not find a sex predilection
between dogs with benign or malignant lesions; however,
the large majority of the study population was spayed and
castrated. The authors speculate that the reason for the
prevalence of gonadectomy was due to cultural and socioeconomic reasons associated with the suburban New
York geographical area of our study population.
Our study population was similar to previous reports
of SM with respect to breed and weight. In the present
study, the dog breeds found to have concurrent SM and
HM were comparable to those in previous studies of SM,
with mixed breed, Golden Retrievers, Labrador Retrievers, and German Shepherd Dogs being overrepresented
[4, 5, 15, 18, 19].
Further prospective studies are warranted and should
be directed at quantification and characterization of SM
and HM with different imaging modalities and gross
examination. Clendaniel et al. [11] previously noted that

multiple nodules, dark-colored nodules, and actively
bleeding nodules were highly associated with malignancy
of the liver. A study utilizing contrast harmonic ultrasonography of splenic masses and liver nodules showed
that it was 100% sensitive and specific for differentiating
a benign vs malignant processes of the liver; however, the
same study found that benign and malignant processes
of the spleen were indistinguishable utilizing the same
modality [15]. Another study accurately differentiated
benign from malignant focal hepatic and splenic lesions
in dogs with magnetic resonance imaging; the overall
sensitivity and specificity were 100 and 90%, respectively
[21]. Cuccovillo et al. [22] noted a positive predictive
value of 74% for malignancy when one target lesion was
visualized and an 81% positive predictive for malignancy
if multiple target lesions were noted in the liver or the
spleen on ultrasonography. Future studies should utilize
the above mentioned modalities and visual characteristics in series or parallel to better prognosticate cases with
SM and HM.
Conclusions

Our data suggests that nearly 30% of dogs undergoing surgery with both gross hepatic and splenic lesions
have a favorable prognosis. While malignant neoplasia
is most likely in cases with both SM and HM undergoing splenectomy, benign or treatable causes must
be considered possible in each dog. This information
should be provided to owners to facilitate making an
informed decision of whether or not to pursue surgery
after imaging.

Limitations
Limitations of the study were mainly due to the retrospective nature. Only cases that underwent surgery
were included in our study. At our hospital, preoperative abdominal ultrasonography is routinely performed.

Leyva et al. BMC Res Notes (2018) 11:122

Given that cases with suspected metastatic disease based
on preoperative imaging were likely relayed to owners as
such, a sampling bias is probable. The owners of those
dogs may have elected euthanasia or palliative therapy at
a higher rate than those of other dogs. Thus, our study
population may be skewed towards a more favorable
prognosis. However, at our hospital we do not recommend euthanasia to owners just on the fact that lesions
are noted on both organs and always mention that longterm prognosis would be based on histopathology results.

Additional file
Additional file 1. Supplemental descriptive and inferential statistics.
Analyses conducted in order to examine the association between patient
age, weight, sex, and malignancies of the spleen and liver.
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